ML355

Catalog No.S6557 Batch:S655702

Print

Technical Data

Formula

C21H19N3O4S2
Molecular Weight 441.52 CAS No. 1532593-30-8
Solubility (25°C)* In vitro DMSO 88 mg/mL (199.31 mM)
Water Insoluble
Ethanol Insoluble
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
* Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description ML355 is a potent and selective inhibitor of human 12-Lipoxygenase with an IC50 of 290 nM and shows excellent selectivity over related lipoxygenases and cyclooxygenases.
Targets
12-LOX [1]
In vitro

ML355 displays nM potency against 12-LOX and excellent selectivity over related lipoxygenases and cyclooxygenases[1].
In vivo

In vivo PK studies where ML355 is administered as a solution via IV (3mpk) and PO (30mpk) demonstrated that ML355 is orally bioavailable (%F = 20) with good half-life (T1/2 = 2.9 hours). At 30 mpk dosing, ML355 achieves a Cmax of over 135 times the in vitro IC50 and remains over IC50 value for over 12 hours. The compound has low clearance (3.4 mL/min/kg) and good overall exposure (AUCinf) of 38 µM. Although, the volume of distribution (VD) observed is low (0.55 L/kg), the rest of the PK profiling results suggest a reasonable distribution between tissue and blood[1].

Protocol (from reference)

Cell Assay:

[2]
  • Cell lines

    U87 cells

  • Concentrations

    10 µM

  • Incubation Time

    24 h

  • Method

    Cells were treated with indicated concentration of drug for 24 h.
Animal Study:

[3]
  • Animal Models

    C57BL/6 mice

  • Dosages

    15 or 30 mg/kg

  • Administration

    p.o.

Selleck's ML355 has been cited by 5 publications

Identification and Validation of a Novel Prognostic Signature Based on Ferroptosis-Related Genes in Ovarian Cancer [ Vaccines (Basel), 2023, 11(2)205] PubMed: 36851083
Identification and Validation of a Novel Prognostic Signature Based on Ferroptosis-Related Genes in Ovarian Cancer [ Vaccines (Basel), 2023, 11(2)205] PubMed: 36851083
Phospholipid peroxidation inhibits autophagy via stimulating the delipidation of oxidized LC3-PE [ Redox Biol, 2022, 55:102421] PubMed: 35964342
miR-18a promotes glioblastoma development by down-regulating ALOXE3-mediated ferroptotic and anti-migration activities [ Oncogenesis, 2021, 10(2):15] PubMed: 33579899
Lipid Receptor GPR31 (G-Protein-Coupled Receptor 31) Regulates Platelet Reactivity and Thrombosis Without Affecting Hemostasis [ Arterioscler Thromb Vasc Biol, 2020, ATVBAHA120315154] PubMed: 33267659

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.